117 studies found for:    Open Studies | "Hemophilia A"
Show Display Options
Rank Status Study
21 Not yet recruiting National Study of a Pharmacokinetic-Focused Educational Package for Patients With Severe Haemophilia A
Condition: Hemophilia A
Intervention: Behavioral: Educational Package
22 Unknown  Personalized Prediction of Tolerance and Immunogenicity in Hemophilia
Condition: Hemophilia A
Intervention:
23 Not yet recruiting Hemophilia Inhibitor Prevention (INHIBIT) Trial
Condition: Severe Hemophilia A
Intervention: Drug: Long-acting recombinant factor VIII Fc fusion protein
24 Recruiting Subclinical Joint Bleeding in Irish Adults With Severe Haemophilia A on Personalised Prophylaxis Regimens
Condition: Severe Haemophilia A
Intervention: Drug: ADVATE [Antihemophilic Factor (Recombinant)]
25 Recruiting Study of Recombinant Factor VIIa Fusion Protein (rVIIa-FP, CSL689) for On-demand Treatment of Bleeding Episodes in Patients With Hemophilia A or B With Inhibitors
Conditions: Hemophilia A With Inhibitors;   Hemophilia B With Inhibitors
Interventions: Drug: CSL689;   Drug: Eptacog alfa (activated)
26 Recruiting ADVATE Hemophilia A Outcome Database (AHEAD)
Condition: Hemophilia A
Intervention: Biological: Antihemophilic Factor (Recombinant) - Plasma/Albumin Free Method
27 Recruiting A Non-interventional Retrospective Study of the Current Treatment Practice in European Haemophilia Care
Conditions: Haemophilia A;   Haemophilia B
Intervention:
28 Recruiting A Single Escalating Dose Study of BAY 1093884 in Subjects With Severe Hemophilia Types A or B, With or Without Inhibitors
Conditions: Hemophilia A;   Hemophilia B
Intervention: Drug: BAY1093884
29 Recruiting PF-05208756, Moroctocog Alfa (AF-CC), Xyntha For Hemophilia A
Condition: Hemophilia A
Intervention: Drug: Intravenous infusions of Xyntha
30 Recruiting Evaluating the Haemostatic Effect of NNC 0129-0000-1003 During Surgical Procedures in Subjects With Haemophilia A
Conditions: Congenital Bleeding Disorder;   Haemophilia A
Intervention: Drug: turoctocog alfa pegol
31 Recruiting 2-cohort Study of Adult Patients With Severe Hemophilia A in Greece
Condition: Hemophilia A
Intervention: Other: Survey
32 Unknown  Safety and Efficacy Extension Study of GreenGene™ F in Previously Treated Patients Diagnosed With Severe Hemophilia A
Condition: Hemophilia A
Intervention: Biological: GreenGene™ F
33 Recruiting Patient Functioning and Well-being, Economic, and Clinical Impact of Hemophilia A and Its Treatment
Condition: Hemophilia A
Intervention: Drug: Available Recombinant, and Human Factor VIII products incl. Kogenate FS (Recombinant Factor VIII, BAY14-2222)
34 Recruiting Safety, Efficacy and Pharmacokinetics of GreenGene™ F to Previously Treated Patients With Severe Hemophilia A
Condition: Hemophilia A
Interventions: Biological: GreenGene™ F and an approved recombinant Factor VIII product;   Biological: GreenGene™ F
35 Recruiting To Investigate Safety and Efficacy of NovoEight® (rFVIII) During Long-term Treatment of Haemophilia A in Japan
Conditions: Congenital Bleeding Disorder;   Haemophilia A
Intervention: Drug: turoctocog alfa
36 Recruiting Safety and Efficacy of Turoctocog Alfa in Prevention and Treatment of Bleeds in Previously Untreated Children With Haemophilia A
Conditions: Congenital Bleeding Disorder;   Haemophilia A
Intervention: Drug: turoctocog alfa
37 Recruiting Phase 3 Efficacy and Safety Study of BAX 855 in Severe Hemophilia A Patients Undergoing Surgical Procedures
Condition: Hemophilia A
Intervention: Biological: PEGylated Recombinant factor VIII (rFVIII)
38 Recruiting Phase 3b Continuation Study of the Safety and Efficacy of Prophylactic BAX 855 in PTPs With Severe Hemophilia A
Condition: Hemophilia A
Intervention: Biological: PEGylated Recombinant Factor VIII
39 Not yet recruiting Retrospective Chart Review to Evaluate Safety and Tolerability of ADVATE Among Previously Untreated Patients in China With Moderate to Severe Hemophilia A
Condition: Hemophilia A
Intervention: Biological: Octocog alfa (recombinant human coagulation factor VIII)
40 Recruiting Trial Investigating Safety, Pharmacokinetics and Pharmacodynamics of Concizumab Administered Subcutaneously to Haemophilia A Subjects
Conditions: Congenital Bleeding Disorder;   Haemophilia A
Interventions: Drug: Concizumab;   Drug: placebo

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years